CancerVax

Name

CancerVax

Legal name

CancerVax, Inc.

Website

http://www.cancervax.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

akta.pro secondary industries

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)

Keywords

• Cancer immunotherapy platform
• Lipid nanoparticle therapeutics
• MRNA cancer treatment
• Preclinical oncology research
• Universal cancer vaccine

Headquarters

HQ city

Rockville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Biopharmaceutical Product Sales: Pre-clinical stage company developing a Universal Cancer Treatment Platform. The intended revenue model is through commercialization of therapeutic cancer treatments as injectable pharmaceuticals, once preclinical studies and clinical trials are successfully completed and regulatory approvals obtained.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

CancerVax is a pre-clinical biotechnology company developing a single Universal Cancer Treatment Platform that uses proprietary lipid nanoparticles (LNPs) delivering Smart mRNA payloads to detect, mark, and kill cancer cells. The platform employs a dual-marker targeting mechanism (Marker1 for cell-surface detection and Marker2 for genetic-signature confirmation) that forces cancer cells to produce viral proteins, disguising them as well-known pathogens (e.g., measles) to trigger the body's pre-existing immune response. The intended commercial offering is an off-the-shelf injectable therapeutic, customizable by cancer type, initially targeting pancreatic, liver, bile duct, and colorectal cancers.

Product overview

CancerVax is a preclinical-stage biotech company developing a single, unified Universal Cancer Treatment Platform — not a multi-product portfolio. The platform consists of a customizable lipid nanoparticle (LNP) that uses a two-step dual-marker targeting mechanism (Marker1 for cell-surface detection and Marker2 for genetic signature confirmation) to deliver proprietary Smart mRNA payloads into cancer cells, forcing them to produce viral proteins (e.g., measles, chickenpox) that 'disguise' the cancer as a recognized pathogen. The body's existing immune system then mounts a strong attack against these disguised cells. The platform is designed to be customized by cancer type (not per patient), enabling off-the-shelf injections. Target indications include pancreatic ductal adenocarcinoma (PDAC), intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC), and colorectal cancer.

Differentiator

Problem solved

Functional benefit

Products and services

• Universal Cancer Treatment Platform

Quantifiable outcome

• Reduced liver accumulation demonstrated in mouse biodistribution studies with significantly lower ALT/AST and total bilirubin markers compared to conventional LNPs
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• Cytiva (Danaher)coreTechnology or IntegrationCytiva, owned by Danaher (NYSE: DHR, ~$170B+ market cap), formerly Precision NanoSystems, is a global leader in LNP development and biomanufacturing solutions. CancerVax is working with Cytiva to leverage its clinically proven LNPs to create a complete CancerVax therapeutic nanoparticle.
• Charles River LaboratoriescoreImplementation/ SI/ Consulting PartnerCharles River (NYSE: CRL, ~$10B+ market cap) provides essential products and services to help pharmaceutical and biotechnology companies accelerate research and drug development. They offer preclinical contract research services supporting CancerVax's development program.
• TriLink BioTechnologies (Maravai LifeSciences)coreTechnology or IntegrationTriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI, ~$1-2B), is a global leader in nucleic acid and mRNA solutions including its patented CleanCap mRNA capping technology. They provide mRNA expertise and materials supporting CancerVax's Smart mRNA development.
• Crown BiosciencesupportingTechnology or IntegrationFounded 2006, headquartered in San Diego, California with 13 facilities across US, Europe, and Asia-Pacific. Crown Bioscience operates the world's largest commercially available patient-derived xenograft (PDX) collection and offers over 600 tumor organoid models. Named Best Preclinical Oncology CRO in 2025 Healthcare and Pharmaceutical Awards.
• Axis Bio (QIMA Life Sciences)supportingTechnology or IntegrationAxis Bio is a preclinical contract research organization with specialist capabilities in oncology, inflammation and respiratory diseases. Services range from in vitro efficacy and mechanistic studies to in vivo target engagement studies, providing CancerVax with preclinical efficacy testing capabilities.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• BioNTech: Direct peer developing mRNA-based cancer immunotherapies including individualized neoantigen vaccines (e.g., BNT122) and off-the-shelf mRNA cancer vaccines. Operates the FixVac and iNeST platforms that overlap directly with CancerVax's mRNA + LNP approach to solid tumors.
• Moderna: Direct peer with a leading mRNA therapeutics platform that includes oncology vaccines (e.g., mRNA-4157/V940 with Merck in melanoma and other solid tumors). Combines mRNA payloads with lipid nanoparticles and pursues both personalized and off-the-shelf cancer immunotherapy strategies directly comparable to CancerVax's positioning.
• CureVac: Direct peer developing mRNA-based cancer immunotherapies using lipid nanoparticle delivery, with clinical-stage programs in solid tumors. Targets overlapping indications (e.g., melanoma, prostate cancer) with a similar mRNA + LNP modality.
• Arcturus Therapeutics: Direct peer combining lipid nanoparticle delivery with self-amplifying mRNA and conventional mRNA for cancer immunotherapy and rare diseases. Has clinical-stage oncology programs (e.g., ARCT-021, ARCT-032) and operates a STARR mRNA + LNP platform that is highly comparable to CancerVax's technology.

Emerging players

• Strand Therapeutics: Emerging player developing synthetic biology mRNA therapies for cancer using programmable, self-replicating mRNA payloads delivered via LNPs. Pursues solid tumor immunotherapy with a novel mechanism comparable to CancerVax's disguising approach, though at an earlier pre-clinical/IND-enabling stage.
• Replimune: Emerging player developing oncolytic virus immunotherapies for solid tumors, with clinical-stage programs in melanoma and other indications. Uses a related mechanistic concept of marking tumor cells for immune attack, though delivered via viral vectors rather than LNPs.
• Lyell Immunopharma: Emerging player in cell therapy for solid tumors, including T-cell receptor (TCR) therapies and TIL-based approaches. The company's Chief Scientific Advisor (Sumant Ramachandra) sits on Lyell's board, creating an indirect but real link in immuno-oncology strategy and advisory network.
• BioLineRx (or other pre-clinical LNP-immunotherapy): Emerging oncology company at similar pre-clinical/early-clinical stage developing novel cancer immunotherapies. Comparable in scale, funding model (public small-cap), and development stage to CancerVax's current position in the immuno-oncology landscape.

Broad incumbents

• Poseida Therapeutics: Broader incumbent in cell and gene therapy with a non-viral LNP-based delivery platform for CAR-T and gene editing applications. The company's Chief Medical Officer (Matthew Spear, MD) previously led CAR-T development at Poseida, creating a network link and a platform-comparable peer using LNPs for genetic medicines.

Others

• Maravai LifeSciences (TriLink BioTechnologies): Adjacent enabling vendor supplying mRNA capping technology (CleanCap) and mRNA manufacturing services to CancerVax (as a disclosed core partner). Comparable as a peer of the broader mRNA + LNP ecosystem in which CancerVax operates, though not a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@CancerVAX
• Facebookfacebook.com/CancerVAX
• LinkedInlinkedin.com/company/49710

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds7 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CancerVax